MXi Pharmaceuticals has recieved approval to begin a trial for ovarian/uterine cancer. The company hopes to start enrolling patients this calendar year.
See the news release here
Enroll in clinical trials here
Ovarian Cancer National Alliance • 901 E Street NW, Suite 405 • Washington, DC 20004
(202) 331-1332 • toll-free: 1-866-399-6262 • fax: (202) 331-2292 • email@example.com
All content © Copyright 2013 by Ovarian Cancer National Alliance.
Subscribe to our RSS Feed or view our Sitemap
This site made possible by a grant from Novartis Oncology